RT Journal Article
T1 Novel Urinary Biomarkers For Improved Prediction Of Progressive Egfr Loss In Early Chronic Kidney Disease Stages And In High Risk Individuals Without Chronic Kidney Disease.
A1 Rodriguez-Ortiz, Maria E
A1 Pontillo, Claudia
A1 Rodriguez, Mariano
A1 Zürbig, Petra
A1 Mischak, Harald
A1 Ortiz, Alberto
K1 Albuminuria
K1 Area under curve
K1 Biomarkers
K1 Disease progression
AB Chronic kidney disease is associated with increased risk of CKD progression and death. Therapeutic approaches to limit progression are limited. Developing tools for the early identification of those individuals most likely to progress will allow enriching clinical trials in high risk early CKD patients. The CKD273 classifier is a panel of 273 urinary peptides that enables early detection of CKD and prognosis of progression. We have generated urine capillary electrophoresis-mass spectrometry-based peptidomics CKD273 subclassifiers specific for CKD stages to allow the early identification of patients at high risk of CKD progression. In the validation cohort, the CKD273 subclassifiers outperformed albuminuria and CKD273 classifier for predicting rapid loss of eGFR in individuals with baseline eGFR > 60 ml/min/1.73 m2. In individuals with eGFR > 60 ml/min/1.73 m2 and albuminuria  60 ml/min/1.73 m2. In individuals with eGFR > 60 ml/min/1.73 m2 and albuminuria  60 ml/min/1.73 m2 and albuminuria  60 ml/min/1.73 m2. These CKD273 subclassifiers represented the earliest evidence of rapidly progressive CKD in non-albuminuric individuals with preserved renal function.
PB Nature Publishing Group
YR 2018
FD 2018-10-15
LK http://hdl.handle.net/10668/13140
UL http://hdl.handle.net/10668/13140
LA en
NO Rodríguez-Ortiz ME, Pontillo C, Rodríguez M, Zürbig P, Mischak H, Ortiz A. Novel Urinary Biomarkers For Improved Prediction Of Progressive Egfr Loss In Early Chronic Kidney Disease Stages And In High Risk Individuals Without Chronic Kidney Disease. Sci Rep. 2018 Oct 29;8(1):15940
NO European Union funding through iMODECKD (Clinical and system-omics for the identifcation of the Molecular Determinants of Established Chronic Kidney Disease), FIS ISCIII FEDER funds PI16/02057, PI16/01900, and ISCIII-RETIC REDinREN RD12/0021 and RD16/0009. “Sara Borrell” research contract to ME R-O and Programa Intensifcación Actividad Investigadora to AO (FIS ISCIII, Spain)
DS RISalud
RD Apr 7, 2025